RT Journal Article
T1 Polyphenol Intake and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study.
A1 Londoño, Catalina
A1 Cayssials, Valerie
A1 de Villasante, Izar
A1 Crous-Bou, Marta
A1 Scalbert, Augustin
A1 Weiderpass, Elisabete
A1 Agudo, Antonio
A1 Tjønneland, Anne
A1 Olsen, Anja
A1 Overvad, Kim
A1 Katzke, Verena
A1 Schulze, Matthias
A1 Palli, Domenico
A1 Krogh, Vittorio
A1 Santucci de Magistris, Maria
A1 Tumino, Rosario
A1 Ricceri, Fulvio
A1 Gram, Inger T
A1 Rylander, Charlotta
A1 Skeie, Guri
A1 Sanchez-Perez, Maria-Jose
A1 Amiano, Pilar
A1 Huerta, José María
A1 Barricarte, Aurelio
A1 Sartor, Hanna
A1 Sonestedt, Emily
A1 Esberg, Anders
A1 Idahl, Annika
A1 Mahamat-Saleh, Yahya
A1 Laouali, Nasser
A1 Kvaskoff, Marina
A1 Turzanski-Fortner, Renée
A1 Zamora-Ros, Raul
K1 EPIC
K1 cohort
K1 flavonoids
K1 intake
K1 ovarian cancer
K1 polyphenols
AB Despite some epidemiological evidence on the protective effects of polyphenol intake on epithelial ovarian cancer (EOC) risk from case-control studies, the evidence is scarce from prospective studies and non-existent for several polyphenol classes. Therefore, we aimed to investigate the associations between the intake of total, classes and subclasses of polyphenols and EOC risk in a large prospective study. The study was conducted in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, which included 309,129 adult women recruited mostly from the general population. Polyphenol intake was assessed through validated country-specific dietary questionnaires and the Phenol-Explorer database. During a mean follow-up of 14 years, 1469 first incident EOC cases (including 806 serous, 129 endometrioid, 102 mucinous, and 67 clear cell tumours) were identified. In multivariable-adjusted Cox regression models, the hazard ratio in the highest quartile of total polyphenol intake compared with the lowest quartile (HRQ4vsQ1) was 1.14 (95% CI 0.94-1.39; p-trend = 0.11). Similarly, the intake of most classes and subclasses of polyphenols were not related to either overall EOC risk or any EOC subtype. A borderline statistically significant positive association was observed between phenolic acid intake (HRQ4vsQ1 = 1.20, 95% CI 1.01-1.43; p-trend = 0.02) and EOC risk, especially for the serous subtype and in women with obesity, although these associations did not exceed the Bonferroni correction threshold. The current results do not support any association between polyphenol intake and EOC in our large European prospective study. Results regarding phenolic acid intake need further investigation.
PB MDPI AG
SN 2076-3921
YR 2021
FD 2021-08-02
LK http://hdl.handle.net/10668/18421
UL http://hdl.handle.net/10668/18421
LA en
NO Londoño C, Cayssials V, de Villasante I, Crous-Bou M, Scalbert A, Weiderpass E, et al. Polyphenol Intake and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Antioxidants (Basel). 2021 Aug 4;10(8):1249.
NO This research was funded by the Women’s Health Dexeus Foundation (R.Z.-R.). The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). We thank CERCA Program/Generalitat de Catalunya for institutional support. R.Z.-R. would like to thank the “Miguel Servet” program (CPII20/00009) from the Institute of Health Carlos III (Spain) and the European Social Fund (ESF).
DS RISalud
RD Apr 6, 2025